Centrosome associated genes pattern for risk sub-stratification in multiple myeloma

Table 2 Survival characteristics for different TP53 risk groups sub-stratified with CAGP model

Stratification group	N	HR (95 % CI)	Survival median (months)	3-years outcome (%)	p value (log-rank)
Overall survival
Low risk CAGP	66		38.8	53.8	<0.00799
High risk CAGP	84	1.8 (1.16; 2.80)	22.1	25.1	<0.00799
TP53−	110		25.1	35.6	<0.00281
TP53+	14	2.5 (1.35; 4.73)	12.8	12.2	<0.00281
TP53−/low risk CAGP	47		38.8	61.1	<0.00099
TP53−/high Risk CAGP	63	2.5 (1.41; 4.30)	22.2	20.1	<0.00099
TP53+/low Risk CAGP	7		12.8	0	<0.3621
TP53+/high risk CAGP	7	0.5 (0.14; 2.05)	16.7	21.4	<0.3621
Time to progression
Low risk CAGP	66		13.6	11.5	<0.1939
High risk CAGP	84	1.3 (0.88; 1.88)	13.0	8.7	<0.1939
TP53−	110		13.9	11.6	<0.01378
TP53+	14	2.1 (1.15; 3.79)	8.7	0	<0.01378
TP53−/low risk CAGP	47		16.4	15.3	<0.08914
TP53−/high risk CAGP	63	1.5 (0.94; 2.34)	13.2	8.0	<0.08914
TP53+/low risk CAGP	7		7.6	0	<0.676
TP53+/high risk CAGP	7	0.8 (0.23; 2.61)	9.9	0	<0.676
Progression free survival
Low risk CAGP	66		12.6	10.8	<0.06232
High risk CAGP	84	1.4 (0.98; 2.03)	10.2	5.6	<0.06232
TP53−	110		13.2	8.8	<0.04351
TP53+	14	1.8 (1.01; 3.29)	8.7	0	<0.04351
TP53−/low risk CAGP	47		15.2	14.1	<0.02102
TP53−/high risk CAGP	63	1.7 (1.07; 2.55)	11.3	4.6	<0.02102
TP53+/low risk CAGP	7		7.6	0	<0.676
TP53+/high risk CAGP	7	0.8 (0.23; 2.61)	9.9	0	<0.676

Low risk CAGP” group includes patients with “Low expressed” centrosome associated gene pattern. “High risk CAGP” group includes patients with united “High and medium expressed” centrosome associated gene pattern. “TP53+” group includes patients with deletion 17p13; “TP53−” group includes patients without deletion 17p13 (positivity cut-off >20 %)

ISSN: 1479-5876